Interestingly, sodium-glucose cotransporter 2 inhibitors (SGLT2is), which have renoprotective effects in CKD, have been demonstrated to stimulate hepatic BHOB production.30,31 Specific studies in which the rise in plasma BHOB is prevented after SGLT2i treatment will clarify the role of increased ketone production in the protective benefits of these inhibitors against the development of CKD. Here, SLC5A2 is linked to chronic kidney disease.